Market Research Logo

TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions (North America, Europe, Asia Pacific, Rest of the World) – Global Forecast up to

Global TNF Alpha Inhibitors Market By Drug Class (Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab), By Pipeline Analysis (Phase I, Phase II, Phase III), By Regions (North America, Europe, Asia Pacific, Rest of the World): Global Forecast up to 2025

This market research report includes a detailed segmentation of the global TNF alpha inhibitors market by drug class (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab), pipeline analysis (phase I, phase II, and phase III), and regions (North America, Europe, Asia Pacific, and Rest of the World).

verview of the Global TNF Alpha Inhibitors Market Research:

Infoholic’s market research report predicts that the global TNF alpha inhibitors market will grow at a CAGR of 3.6% during the forecast period 2019–2025. TNF inhibitors, also known as TNF blockers, anti-TNF drugs, and biologic therapies, are a cluster of medications used to treat inflammatory conditions, including rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (Crohn’s and ulcerative colitis), and psoriasis. The drugs decrease inflammation and can stop disease development by targeting an inflammation-causing substance, tumor necrosis factor (TNF).

The market is witnessing the loss of patents in Europe for various blockbuster drugs, resulting in the emergence of biosimilars. In April 2019, Eticovo – a biosimilar from Samsung Bioepis to Amgen’s Enbrel (etanercept), received FDA approval. In November 2018, FDA approved Hyrimoz developed by Sandoz, a biosimilar to AbbVie’s blockbuster drug Humira, which will be launched in the US market by 2023. Currently, only five approved TNF inhibitors, i.e., adalimumab, certolizumab, etanercept, golimumab, and infliximab, control the market. The wide application of these drugs for numerous autoimmune diseases ensures constant growth of the market during the forecast period 2019–2025.



Key players operating in this field, i.e., AbbVie Inc., Amgen Inc., Johnson & Johnson, and Celgene Corporation, are generating the majority of the revenue in the global TNF alpha inhibitors market.

According to Infoholic Research analysis, North America accounted for the largest share of the global TNF alpha inhibitors market in 2018 and will retain a high position during the forecast period. North America is followed by Europe, with a market share of more than 20% in 2018.

By Drug Class:

  • Adalimumab
  • Certolizumab Pegol
  • Etanercept
  • Golimumab
  • Infliximab
In 2018, the adalimumab segment accounted for the largest share and is expected to grow at a mid-single-digit CAGR during the forecast period. Increased clinical efficacy and high preference by physicians for the treatment of severe rheumatic diseases made the segment the largest shareholder in 2018. Golimumab is expected to grow at a high CAGR during the forecast period 2019–2025.

Pipeline Analysis:
  • Phase I
  • Phase II
  • Phase III
Many companies are making huge investments to develop products and enter the market as soon as biologics lose their patents. Among various TNF alpha inhibitors, adalimumab has the highest number of ongoing clinical trials, followed by certolizumab pegol.

By Regions:
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
Based on geography, North America dominated the market in 2018 with a market share of over 60% and is expected to maintain this position during the forecast period. Europe is projected to grow at a high CAGR during the forecast period. The increasing acceptance of biosimilars and increasing investments in the R&D of new drugs make Europe the fastest-growing region during the forecast period.

Global TNF Alpha Inhibitors Market Research Competitive Analysis: The market is growing at a steady rate, i.e., at a CAGR of 3.6% during the forecast period 2019–2025. New drug launches, product approvals, strategic partnerships, and collaborations are among the significant strategies adopted by market leaders to maintain their leadership position. For instance, in July 2019, the US FDA approved HADLIMA by Samsung Bioepis, a biosimilar referencing HUMIRA, to treat juvenile idiopathic arthritis, adult Crohn’s disease, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, rheumatoid arthritis, and plaque psoriasis. In March 2019, the US FDA approved Cimzia injection to treat non-radiographic axial spondyloarthritis (nr-axSpA) in adults, with detached signs of swelling making it the first-ever FDA approved treatment fulfilling the unmet needs for nr-axSpA; and in May 2018, the drug was approved for the treatment of moderate-to-severe plaque psoriasis.

The rising incidence of chronic autoimmune diseases has led to the increasing launch of biosimilars globally. In May 2019, Fresenius Kabi launched biosimilar adalimumab IDACIO in Germany. In May 2019, Janssen launched Simponi Autoinjector in Japan, and the drugs are distributed by Mitsubishi Tanabe. In addition, other leading vendors are focusing on hugely investing in R&D activities to develop new drugs to obtain a high share in the market.

Key Vendors:
  • AbbVie Inc.
  • Novartis AG
  • Amgen Inc.
  • Johnson & Johnson
  • Celgene Corporation
  • Celltrion Healthcare
  • Samsung Bioepis Co. Ltd.
  • Apogenix
  • 3SBIO Inc.
  • Shanghai CP Guojian Pharmaceutical Co. Ltd.
Key Competitive Facts:
  • UCB Biopharma S.P.R.L. is conducting a phase 3 clinical trial in 15 centers in Germany to study “Efficacy and safety of certolizumab pegol (CZP) versus active comparator and placebo in subjects with Plaque Psoriasis (PSO) (CIMPACT)”.
  • Globally, over 95% of the clinical trials of certolizumab are conducted by UCB Pharma.
  • In July 2018, Mylan made a patent license agreement with AbbVie over Mylan’s proposed Humira biosimilar. Under the terms of the agreement, AbbVie will grant Mylan exclusive licenses on Humira’s intellectual properties on July 31, 2023 in the US and other countries excluding Europe.
Benefits – The report provides complete details about the sub-segment of the global TNF alpha inhibitors market. Thus, the key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives toward the pharmaceuticals segment in the upcoming years along with details of the pureplay companies entering the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders in order to expand their business and capture the revenue in specific verticals, and to analyze before investing or expanding the business in this market.

Key Takeaways:
  • Understanding the potential market opportunity with precise market size and forecast data.
  • Detailed market analysis focusing on the growth of TNF alpha inhibitors industry.
  • Factors influencing the growth of the TNF alpha inhibitors market.
  • In-depth competitive analysis of dominant and pure-play vendors.
  • Prediction analysis of the TNF alpha inhibitors industry in both developed and developing regions.
  • Key insights related to major segments of the TNF alpha inhibitors market.
  • Latest market trend analysis impacting the buying behavior of the consumers.
Key Stakeholders:


1 Industry Outlook 10
1.1 Industry Overview 10
1.1.1 Global Driver for Pharmaceutical Demand 11
1.1.2 R&D Pipeline in Pharmaceutical Industry 11
1.1.3 Top Pharma Drugs by Sales ($Million) 11
1.2 Industry Trends 12
1.3 Total Addressable Market 13
1.4 Trends of the Immunotherapy Drugs Market 13
2 Report Outline 15
2.1 Report Scope 15
2.2 Report Summary 15
2.3 Research Methodology 16
2.4 Report Assumptions 16
3 Market Snapshot 18
3.1 Market Definition – Infoholic Research 18
3.2 Segmented Addressable Market (SAM) 18
3.3 Trends of the TNF Alpha Inhibitors Market 18
3.4 Related Markets 19
3.4.1 Oncology Drugs 19
3.4.2 Biologics 20
3.4.3 Biosimilars 20
4 Market Outlook 22
4.1 Market Segmentation 22
4.2 PEST Analysis 23
4.3 Porter 5(Five) Forces 24
5 Market Characteristics 25
5.1 DRO – Global TNF Alpha Inhibitors Market Dynamics 25
5.1.1 Drivers 25
5.1.1.1 Increasing prevalence of chronic autoimmune disease 25
5.1.1.2 Constant research to develop target-based biologics 26
5.1.2 Opportunities 26
5.1.2.1 Continuous development of biosimilars 26
5.1.2.2 Increasing opportunities in the emerging market 27
5.1.3 Restraints 27
5.1.3.1 Complex drug development process 27
5.1.3.2 Patent expiry 28
5.2 DRO – Impact Analysis 29
5.3 Key Stakeholders 30
6 Product: Market Size and Analysis 31
6.1 Overview 31
6.2 Adalimumab 32
6.3 Certolizumab Pegol 36
6.4 Etanercept 38
6.5 Golimumab 42
6.6 Infliximab 43
7 Pipeline Analysis: Market Size and Analysis 47
7.1 Overview 47
7.2 Phase I 47
7.3 Phase II 51
7.4 Phase III 54
8 Regions: Market Size and Analysis 66
8.1 Overview 66
8.2 North America 67
8.2.1 Overview 67
8.2.2 US 72
8.2.3 Canada and Others 75
8.3 Europe 77
8.3.1 Overview 77
8.3.2 UK 82
8.3.3 Germany 83
8.3.4 Russia and Ukraine 84
8.3.5 Turkey 85
8.4 Asia Pacific 86
8.4.1 Overview 86
8.4.2 India 91
8.4.3 Pakistan 92
8.4.4 Indonesia 92
8.4.5 Thailand 93
8.5 Rest of the World 93
8.5.1 Overview 93
8.5.2 Mexico 98
8.5.3 Brazil 98
8.5.4 Middle East and Africa 99
9 Competitive Landscape 100
10 Vendors Profile 102
10.1 AbbVie Inc. 102
10.1.1 Overview 102
10.1.2 Geographic Revenue 105
10.1.3 Business Focus 105
10.1.4 SWOT Analysis 106
10.1.5 Business Strategies 106
10.2 Novartis AG 107
10.2.1 Overview 107
10.2.2 Business Units 112
10.2.3 Geographic Revenue 113
10.2.4 Business Focus 113
10.2.5 SWOT Analysis 114
10.2.6 Business Strategies 114
10.3 Amgen Inc. 115
10.3.1 Overview 115
10.3.2 Geographic Revenue 120
10.3.3 Business Focus 120
10.3.4 SWOT Analysis 121
10.3.5 Business Strategies 121
10.4 Johnson & Johnson 122
10.4.1 Overview 122
10.4.2 Business Units 126
10.4.3 Geographic Revenue 127
10.4.4 Business Focus 127
10.4.5 SWOT Analysis 128
10.4.6 Business Strategies 128
10.5 Celgene Corporation 129
10.5.1 Overview 129
10.5.2 Geographic Revenue 132
10.5.3 Business Focus 132
10.5.4 SWOT Analysis 133
10.5.5 Business Strategies 133
11 Companies to Watch For 134
11.1 Apogenix 134
11.1.1 Overview 134
11.2 Celltrion Healthcare 135
11.2.1 Overview 135
11.3 Samsung Bioepis Co. Ltd. 136
11.3.1 Overview 136
11.4 3SBio Inc. 138
11.4.1 Overview 138
11.5 Shanghai CP Guojian Pharmaceutical Co. Ltd. 139
11.5.1 Overview 139
Annexure 140
Abbreviations 140
Tables
TABLE 1 DRUG CLASS AND THEIR FDA APPROVED INDICATIONS 31
TABLE 2 GLOBAL TNF ALPHA INHIBITOR MARKET REVENUE, BY PRODUCT, 2018–2025 ($MILLION) 32
TABLE 3 DRUG OVERVIEW: ADALIMUMAB 32
TABLE 4 BIOSIMILARS AND NON-ORIGINATOR BIOLOGICALS OF ADALIMUMAB APPROVED OR IN
DEVELOPMENT 34
TABLE 5 DRUG OVERVIEW: CERTOLIZUMAB PEGOL 36
TABLE 6 BIOSIMILARS AND NON-ORIGINATOR BIOLOGICALS OF CERTOLIZUMAB PEGOL IN DEVELOPMENT 37
TABLE 7 DRUG OVERVIEW: ETANERCEPT 38
TABLE 8 BIOSIMILARS AND NON-ORIGINATOR BIOLOGICALS OF ETANERCEPT APPROVED OR
IN DEVELOPMENT 39
TABLE 9 DRUG OVERVIEW: GOLIMUMAB 42
TABLE 10 DRUG OVERVIEW: INFLIXIMAB 43
TABLE 11 BIOSIMILARS AND NON-ORIGINATOR BIOLOGICALS OF INFLIXIMAB IN DEVELOPMENT 45
TABLE 12 MOLECULES IN PIPELINE IN PHASE I 48
TABLE 13 MOLECULES IN PIPELINE IN PHASE II 51
TABLE 14 MOLECULES IN PIPELINE IN PHASE III 54
TABLE 15 GLOBAL TNF ALPHA INHIBITORS DRUGS MARKET REVENUE, BY GEOGRAPHY, 2018–2025
($MILLION) 67
TABLE 16 ABBVIE INC.: OFFERINGS 102
TABLE 17 ABBVIE INC.: RECENT DEVELOPMENTS 102
TABLE 18 NOVARTIS AG: OFFERINGS 107
TABLE 19 NOVARTIS AG: RECENT DEVELOPMENTS 107
TABLE 20 AMGEN INC.: OFFERINGS 115
TABLE 21 AMGEN INC.: RECENT DEVELOPMENTS 115
TABLE 22 JOHNSON & JOHNSON: PRODUCT OFFERINGS 122
TABLE 23 JOHNSON & JOHNSON: RECENT DEVELOPMENTS 122
TABLE 24 CELGENE CORPORATION: OFFERINGS 129
TABLE 25 CELGENE CORPORATION: RECENT DEVELOPMENTS 130
TABLE 26 APOGENIX: SNAPSHOT 134
TABLE 27 APOGENIX: RECENT DEVELOPMENTS 134
TABLE 28 CELLTRION HEALTHCARE: SNAPSHOT 135
TABLE 29 CELLTRION HEALTHCARE: RECENT DEVELOPMENTS 135
TABLE 30 SAMSUNG BIOEPIS CO. LTD.: SNAPSHOT 136
TABLE 31 SAMSUNG BIOEPIS CO. LTD.: RECENT DEVELOPMENTS 136
TABLE 32 3SBIO INC.: SNAPSHOT 138
TABLE 33 3SBIO INC.: RECENT DEVELOPMENTS 138
TABLE 34 SHANGHAI CP GUOJIAN PHARMACEUTICAL CO. LTD.: SNAPSHOT 139
Charts
CHART 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010–2017) 11
CHART 2 PHARMACEUTICAL DRUGS BY SALES, 2018 12
CHART 3 RESEARCH METHODOLOGY OF GLOBAL TNF ALPHA INHIBITORS MARKET 16
CHART 4 GLOBAL TNF ALPHA INHIBITORS MARKET REVENUE, 2018–2025 ($MILLION) 19
CHART 5 SEGMENTATION OF GLOBAL TNF ALPHA INHIBITORS MARKET 22
CHART 6 PEST ANALYSIS OF GLOBAL TNF ALPHA INHIBITORS MARKET 23
CHART 7 PORTER 5 FORCES ON GLOBAL TNF ALPHA INHIBITORS MARKET 24
CHART 8 MARKET DYNAMICS – DRO ANALYSIS 25
CHART 9 DRO – IMPACT ANALYSIS OF GLOBAL TNF ALPHA INHIBITORS MARKET 29
CHART 10 KEY STAKEHOLDERS 30
CHART 11 HUMIRA ANNUAL REVENUE, 2011–2018 ($MILLION) 33
CHART 12 ADALIMUMAB DRUGS MARKET REVENUE, 2018–2025 ($MILLION) 35
CHART 13 PIPELINE ANALYSIS OF ADALIMUMAB 36
CHART 14 CIMZIA ANNUAL REVENUE, 2011–2018 ($MILLION) 37
CHART 15 CERTOLIZUMAB PEGOL MARKET REVENUE, 2018–2025 ($MILLION) 37
CHART 16 PIPELINE ANALYSIS OF CERTOLIZUMAB PEGOL 38
CHART 17 ETANERCEPT DRUGS MARKET REVENUE, 2018–2025 ($MILLION) 41
CHART 18 PIPELINE ANALYSIS OF ETANERCEPT 41
CHART 19 GOLIMUMAB DRUGS MARKET REVENUE, 2018–2025 ($MILLION) 43
CHART 20 PIPELINE ANALYSIS OF GOLIMUMAB 43
CHART 21 INFLIXIMAB DRUGS MARKET REVENUE, 2018–2025 ($MILLION) 46
CHART 22 PIPELINE ANALYSIS OF INFLIXIMAB 46
CHART 23 GLOBAL TNF ALPHA INHIBITOR DRUGS PIPELINE 47
CHART 24 MOLECULES IN PHASE I 51
CHART 25 MOLECULES IN PHASE II 53
CHART 26 MOLECULES IN PHASE III 65
CHART 27 GLOBAL TNF ALPHA INHIBITORS DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2018 (%) 66
CHART 28 TNF ALPHA INHIBITORS DRUGS MARKET REVENUE IN NORTH AMERICA, 2018–2025 ($MILLION) 68
CHART 29 ADALIMUMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION) 68
CHART 30 ADALIMUMAB NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 69
CHART 31 CERTOLIZUMAB PEGOL NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION) 69
CHART 32 CERTOLIZUMAB PEGOL NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 69
CHART 33 ETANERCEPT NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION) 70
CHART 34 ETANERCEPT NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 70
CHART 35 GOLIMUMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION) 70
CHART 36 GOLIMUMAB NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 71
CHART 37 INFLIXIMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION) 71
CHART 38 INFLIXIMAB NORTH AMERICA MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 71
CHART 39 ADALIMUMAB MARKET REVENUE IN US, 2018–2025 ($MILLION) 72
CHART 40 CERTOLIZUMAB PEGOL MARKET REVENUE IN US, 2018–2025 ($MILLION) 73
CHART 41 ETANERCEPT MARKET REVENUE IN US, 2018–2025 ($MILLION) 74
CHART 42 GOLIMUMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION) 74
CHART 43 INFLIXIMAB NORTH AMERICA MARKET REVENUE, 2018–2025 ($MILLION) 75
CHART 44 TNF ALPHA INHIBITORS DRUGS MARKET REVENUE IN EUROPE, 2018–2025 ($MILLION) 77
CHART 45 ADALIMUMAB EUROPE MARKET REVENUE, 2018–2025 ($MILLION) 78
CHART 46 ADALIMUMAB EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 78
CHART 47 CERTOLIZUMAB PEGOL EUROPE MARKET REVENUE, 2018–2025 ($MILLION) 79
CHART 48 CERTOLIZUMAB PEGOL EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 79
CHART 49 ETANERCEPT EUROPE MARKET REVENUE, 2018–2025 ($MILLION) 80
CHART 50 ETANERCEPT EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 80
CHART 51 GOLIMUMAB EUROPE MARKET REVENUE, 2018–2025 ($MILLION) 80
CHART 52 GOLIMUMAB EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 81
CHART 53 INFLIXIMAB EUROPE MARKET REVENUE, 2018–2025 ($MILLION) 81
CHART 54 INFLIXIMAB EUROPE MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 81
CHART 55 TNF ALPHA INHIBITORS DRUGS MARKET REVENUE IN ASIA PACIFIC, 2018–2025 ($MILLION) 87
CHART 56 ADALIMUMAB ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION) 87
CHART 57 ADALIMUMAB ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 88
CHART 58 CERTOLIZUMAB PEGOL ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION) 88
CHART 59 CERTOLIZUMAB PEGOL ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 88
CHART 60 ETANERCEPT ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION) 89
CHART 61 ETANERCEPT ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 89
CHART 62 GOLIMUMAB ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION) 90
CHART 63 GOLIMUMAB ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 90
CHART 64 INFLIXIMAB ASIA PACIFIC MARKET REVENUE, 2018–2025 ($MILLION) 90
CHART 65 INFLIXIMAB ASIA PACIFIC MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 91
CHART 66 TNF ALPHA INHIBITORS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2018–2025 ($MILLION) 94
CHART 67 ADALIMUMAB ROW MARKET REVENUE, 2018–2025 ($MILLION) 94
CHART 68 ADALIMUMAB ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 95
CHART 69 CERTOLIZUMAB PEGOL ROW MARKET REVENUE, 2018–2025 ($MILLION) 95
CHART 70 CERTOLIZUMAB PEGOL ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 95
CHART 71 ETANERCEPT ROW MARKET REVENUE, 2018–2025 ($MILLION) 96
CHART 72 ETANERCEPT ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 96
CHART 73 GOLIMUMAB ROW MARKET REVENUE, 2018–2025 ($MILLION) 96
CHART 74 GOLIMUMAB ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 97
CHART 75 INFLIXIMAB ROW MARKET REVENUE, 2018–2025 ($MILLION) 97
CHART 76 INFLIXIMAB ROW MARKET REVENUE, BY COUNTRY 2018 (% SHARE) 97
CHART 77 ANNUAL TREATMENT COST 100
CHART 78 ABBVIE INC.: OVERVIEW SNAPSHOT 104
CHART 79 ABBVIE INC.: GEOGRAPHIC REVENUE 105
CHART 80 ABBVIE INC.: SWOT ANALYSIS 106
CHART 81 NOVARTIS AG: OVERVIEW SNAPSHOT 111
CHART 82 NOVARTIS AG: BUSINESS UNITS 112
CHART 83 NOVARTIS AG: GEOGRAPHIC REVENUE 113
CHART 84 NOVARTIS AG: SWOT ANALYSIS 114
CHART 85 AMGEN INC.: OVERVIEW SNAPSHOT 119
CHART 86 AMGEN INC.: GEOGRAPHIC REVENUE 120
CHART 87 AMGEN INC.: SWOT ANALYSIS 121
CHART 88 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT 125
CHART 89 JOHNSON & JOHNSON: BUSINESS UNITS 126
CHART 90 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE 127
CHART 91 JOHNSON & JOHNSON: SWOT ANALYSIS 128
CHART 92 CELGENE CORPORATION: OVERVIEW SNAPSHOT 131
CHART 93 CELGENE CORPORATION: GEOGRAPHIC REVENUE 132
CHART 94 CELGENE CORPORATION: SWOT ANALYSIS 133

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook